Celebrating 60 years of melanoma research to save lives
19 April 2017
Melanoma Institute Australia is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
It was back in 1957 when Sydney Hospital recorded its first data on a melanoma patient. This patient record marked the beginning of what was to become the Melanoma Research Database (MRD), which is now the biggest database of its kind in the world. With more than 41,000 patient records, the MRD continues to play a vital role in underpinning the ground-breaking work of Melanoma Institute Australia (MIA) and around the world.
“Melanoma used to be viewed as a disease with a dismal outlook for patients, but I am pleased to say that today things are much different,” said Professor Richard Scolyer, MIA’s Conjoint Medical Director. “The foresight of our colleagues at Sydney Hospital to start recording patient data back in 1957 set us on a path towards greater understanding of the disease, and we are now leading the world in advancing melanoma treatment and research.”
“Life expectancy for advanced melanoma patients has tripled in the last five years, and we are even seeing some patients who are recovering fully,” comments Professor Georgina Long, MIA’s Conjoint Medical Director. “However we still have a long way to go, with one Australian dying from melanoma every six hours.”
Critical to our story is the work of Professor Gerry Milton (pictured) of the Sydney Melanoma Unit (now Melanoma Institute Australia) who in 1968 was trying to better understand the disease. He recruited Dr Helen Shaw to collect and collate all the records of melanoma patients treated at Sydney Hospital over the previous decade. Always forward thinking, the Unit decided to embrace the “high technology” of the day and convert the entire patient catalogue to punch cards – and so the database was born. The detailed patient records included diagnosis, treatment and disease course over time.
The MRD database is now managed by a team including IT specialists and clinical data managers, dedicated to its refinement, preservation and cultivation. It serves as an invaluable resource to identify and extract specific sub-sets of information for research projects related to causes, diagnosis, prognosis and treatment outcomes in melanoma patients. The knowledge gained from these studies assists in the management of melanoma patients around the world.
“We celebrate this Diamond Anniversary with much gratitude to our professional predecessors for their pioneering work that was way ahead of its time. We also have immense appreciation for those thousands of melanoma patients who over the last 60 years have allowed their clinical records to be included in our research database which have enabled us to improve the lives of melanoma patients that have followed them,” Professor Scolyer said.
“They have quite literally given the gift of life to other melanoma patients, and will be the unsung heroes when we finally achieve our goal of ending melanoma.”
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.